Dupixent shows worth in COPD as FDA date looms

Data have been presented from the NOTUS Phase III study on the use of Dupixent (dupilumab) as an add-on maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease (COPD) on maximal standard-of-care inhaled therapy and evidence of type 2 inflammation.

The NOTUS study confirmed the positive results demonstrated in the Phase III BOREAS study, with its data presented at a late-breaking session of the 2024 American Thoracic Society (ATS) International Conference and simultaneously published in the New England Journal of Medicine (NEJM).

"Dupilumab reduced exacerbations by a magnitude never seen before"Already a blockbuster, Dupixent is being jointly developed by Sanofi (Euronext: SAN) and Regeneron (Nasdaq: REGN) under a global collaboration agreement. To date, it has been studied across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.